BioSpace News Archive

Reviva Pharmaceuticals Holdings, Inc. reported financial results for the third quarter ended September 30, 2022 and summarized recent business highlights.

TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced financial results for the third quarter ended September 30, 2022.

VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”) today announced financial results and a business update for the third quarter ended September 30, 2022.

Tricida, Inc. announced financial results for the three and nine months ended September 30, 2022 and provided an update on key initiatives.

DarioHealth Corp., a leader in the global digital therapeutics market, reported financial results for the third quarter 2022 and provided a corporate and B2B update.

Insulet Corporation, announced a Medical Device Correction for the Omnipod® 5 Automated Insulin Delivery System because of an issue with the Omnipod 5 Controller charging port and cable.

World Orphan Drug Alliance (WODA), a global alliance of full-service regional distributors for orphan drugs, welcomes Decisive Consulting into the Alliance network.

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, announced corporate updates and financial results for the third quarter ended September 30, 2022.

Neoleukin Therapeutics, Inc. announced financial results for the third quarter ended September 30, 2022 as well as a strategic decision to discontinue development of NL-201, a fully de novo IL-2/IL-15 agonist, and focus on advancing next-generation de novo protein therapeutics based on Neoleukin’s expertise in designing and testing novel cytokine mimetics and experience with advanced machine learning.

Icosavax, Inc. reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.